モルヒネの市場規模、シェア、成長分析：形態別、流通チャネル別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

モルヒネの世界市場規模は2023年に300億3,000万米ドルと評価され、2024年の323億4,000万米ドルから2032年には585億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは7.7％で成長する見通しです。

製薬業界の主要セグメントである世界のモルヒネ市場は、特に高齢化層で慢性疼痛が増加する中、強力な鎮痛薬に対する需要の高まりに起因する効果的な疼痛管理ソリューションの提供に注力しています。モルヒネは、がんや術後の回復などの病気に伴う激しい痛みを和らげる役割を果たすため、病院や緩和ケアセンターなどの医療施設におけるその存在は依然として重要です。しかし、この市場には乱用や中毒リスクの可能性といった課題があり、ヘルスケアプロバイダーによる慎重な管理が必要です。こうしたハードルにもかかわらず、技術の進歩、革新的な薬剤の処方、緩和ケアの成長は、市場拡大の大きな機会を浮き彫りにし、最終的には強い痛みを経験する患者の生活の質の向上に貢献します。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

モルヒネ市場規模：形態別& CAGR（2025-2032）

• 市場概要
• 経口錠剤
• 注射
• カプセル
• その他

モルヒネ市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

モルヒネ市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 疼痛管理
• 下痢抑制剤
• 風邪・咳止め
• その他

モルヒネ市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院・クリニック
• 外来手術センター
• その他

モルヒネ市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Mallinckrodt Pharmaceuticals（Ireland）
• Boehringer Ingelheim GmbH（Germany）
• Gerot Lannach（Austria）
• Dongbei Pharmaceutical Group Co.（China）
• Taiji Group Southwest Pharmaceutical Co.（China）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi S.A.（France）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bayer AG（Germany）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）

結論と推奨事項

Global Morphine Market size was valued at USD 30.03 billion in 2023 and is poised to grow from USD 32.34 billion in 2024 to USD 58.55 billion by 2032, growing at a CAGR of 7.7% during the forecast period (2025-2032).

The global morphine market, a key segment of the pharmaceutical industry, is focused on providing effective pain management solutions stemming from rising demands for potent analgesics amid increasing chronic pain conditions, particularly within the aging demographic. As morphine serves to alleviate severe pain associated with ailments like cancer and postoperative recovery, its presence in medical facilities, including hospitals and palliative care centers, remains critical. However, the market grapples with challenges such as potential abuse and addiction risk, necessitating careful management by healthcare providers. Despite these hurdles, advancements in technology, innovative drug formulations, and the growth of palliative care highlight significant opportunities for market expansion, ultimately contributing to improved quality of life for patients experiencing intense pain.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morphine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morphine Market Segmental Analysis

Global Morphine Market is segmented by Form, Distribution Channel, Application, End User and region. Based on Form, the market is segmented into Oral Tablets, Injection, Capsule and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on Application, the market is segmented into Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morphine Market

The global morphine market is significantly influenced by the rising prevalence of chronic pain disorders. An increasing number of individuals suffering from conditions such as cancer, musculoskeletal issues, and neuropathic pain is a key market driver. According to the World Health Organization's projections from 2022, the incidence of cancer cases is expected to rise by almost 50% over the next twenty years. This surge in chronic pain cases has escalated the demand for effective analgesics, particularly morphine, thereby contributing to the overall growth of the morphine market as healthcare providers seek to offer adequate pain management solutions.

Restraints in the Global Morphine Market

The global morphine market encounters significant restraints primarily due to a stringent regulatory environment that governs opioid medications. To combat the growing epidemic of opioid misuse, addiction, and overdose, governments and healthcare authorities have implemented rigorous regulations, including restrictions on prescriptions, monitoring programs, and stringent guidelines for safe usage. While these measures aim to curtail the opioid crisis, they inadvertently pose considerable challenges for manufacturers and healthcare providers, hindering compliance and limiting access to morphine for patients who genuinely require it for medical treatment. Consequently, the balance between ensuring safety and maintaining necessary availability remains a pressing issue within the sector.

Market Trends of the Global Morphine Market

The Global Morphine market is experiencing a significant trend towards personalized pain management, with a growing emphasis on individualized treatment strategies that consider patient-specific characteristics, genetics, and unique pain profiles. This paradigm shift is fueled by advances in pharmacogenomics, which enable healthcare providers to optimize opioid therapy by identifying patients at higher risk for adverse responses. Research, including a pivotal 2022 study in the Journal of Pain and Symptom Management, highlights the potential of tailored approaches to enhance therapeutic outcomes for patients requiring morphine. As the focus on precision medicine intensifies, the demand for morphine is likely to rise, particularly among targeted patient demographics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Morphine Market Size by Form & CAGR (2025-2032)

• Market Overview
• Oral Tablets
• Injection
• Capsule
• Others

Global Morphine Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morphine Market Size by Application & CAGR (2025-2032)

• Market Overview
• Pain Management
• Diarrhea Suppressant
• Cold & Cough Suppressant
• Others

Global Morphine Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Global Morphine Market Size & CAGR (2025-2032)

• North America (Form, Distribution Channel, Application, End User)
  • US
  • Canada
• Europe (Form, Distribution Channel, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Form, Distribution Channel, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Form, Distribution Channel, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Form, Distribution Channel, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerot Lannach (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbei Pharmaceutical Group Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiji Group Southwest Pharmaceutical Co. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations